Pfizer Inc.
PFE
Pozycja w akcjach
#118
Pfizer Inc. is a global biopharmaceutical leader engaged in the research,... Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Cena akcji
$29.47
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$167.94B
Zmiana (1 dzień)
-0.27%
Zmiana (1 rok)
19.34%
Kraj
US
Handel Pfizer Inc. (PFE)
Kategoria
Healthcare
Wskaźnik P/E dla Pfizer Inc. (PFE)
Wskaźnik P/E na dzień October 2026 TTM: 38.60
Według najnowszych raportów finansowych i ceny akcji Pfizer Inc., obecny wskaźnik P/E (TTM) wynosi 38.60. Na koniec 2024 wskaźnik P/E wynosił 18.74.
Historia wskaźnika P/E dla Pfizer Inc. od 2000 do 2026
Wskaźnik P/E na koniec każdego roku
| Rok | Wskaźnik P/E | Zmień |
|---|---|---|
| 2026 (TTM) | 38.60 | 111.95% |
| 2025 | 18.21 | -2.80% |
| 2024 | 18.74 | -75.40% |
| 2023 | 76.17 | 731.36% |
| 2022 | 9.16 | -38.65% |
| 2021 | 14.93 | -33.11% |
| 2020 | 22.33 | 75.65% |
| 2019 | 12.71 | -41.66% |
| 2018 | 21.79 | 126.47% |
| 2017 | 9.62 | -62.98% |
| 2016 | 25.98 | -4.22% |
| 2015 | 27.13 | 31.45% |
| 2014 | 20.64 | 21.52% |
| 2013 | 16.98 | -6.03% |
| 2012 | 18.07 | -1.86% |
| 2011 | 18.42 | 14.15% |
| 2010 | 16.13 | 15.33% |
| 2009 | 13.99 | -0.61% |
| 2008 | 14.08 | -22.47% |
| 2007 | 18.16 | 12.58% |
| 2006 | 16.13 | -24.59% |
| 2005 | 21.39 | 26.25% |
| 2004 | 16.94 | -72.58% |
| 2003 | 61.78 | 216.04% |
| 2002 | 19.55 | -35.41% |
| 2001 | 30.27 | -58.36% |
| 2000 | 72.68 | 0.00% |
Wskaźnik P/E dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/E | Różnica wskaźnika P/E | Kraj |
|---|---|---|---|
| 40.53 | 5.01% |
US
|
|
| 38.50 | -0.26% |
US
|
|
| 79.88 | 106.95% |
US
|
|
| 116.96 | 203.02% |
US
|
|
| 22.25 | -42.36% |
CH
|
Jak odczytywać wskaźnik P/E?
Wskaźnik Cena/Zysk (P/E) mierzy relację między ceną akcji firmy a jej zyskiem na akcję.
Niski, ale dodatni P/E oznacza firmę osiągającą wysokie zyski względem obecnej wyceny i może być niedowartościowana. Wysoki ujemny (bliski 0) P/E wskazuje na duże straty.
Firmy z P/E powyżej 30 lub ujemnym uznaje się zazwyczaj za "akcje wzrostowe", czyli inwestorzy oczekują wzrostu lub przyszłych zysków.
Firmy z dodatnim P/E poniżej 10 uznaje się za "akcje wartościowe", co oznacza, że są już bardzo dochodowe, ale bez dużego potencjału wzrostu.